OraSure Technologies Inc. will increase domestic manufacturing of its InteliSwab Covid-19 rapid test from 8.3 million to 16.7 million tests per month by March 2024 under a new contract with the federal government, according to a source familiar with the award.
The tests are to be made in Bethlehem, Pennsylvania, and will be produced in one more U.S. site. The company will get $109 million under the agreement to make the tests, which are authorized by the Food and Drug Administration.
This deal is part of a $2 billion investment,